Dr. Duane L Haugen, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 3930 Northwoods Dr, Arden Hills, MN 55112 Phone: 651-490-6775 Fax: 651-490-6754 |
Dr. Wallace Jay Anderson, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1260 County Road E West, Arden Hills, MN 55112 Phone: 651-639-0452 |
Dr. Bruce H Hansen, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 3930 Northwoods Dr, Arden Hills, MN 55112 Phone: 651-490-6775 Fax: 651-490-6754 |
Nadine Yacoub, DDS Dentist Medicare: Medicare Enrolled Practice Location: 3930 Northwoods Dr, Arden Hills, MN 55112 Phone: 651-523-8585 |
Dr. Alisa M Madson, DDS, MS Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 3930 Northwoods Drive, Arden Hills, MN 55112 Phone: 651-523-8545 |
Mr. Fouad Badr, DMD Dentist Medicare: Medicare Enrolled Practice Location: 3130 Cleveland Ave N, Arden Hills, MN 55112 Phone: 612-624-6644 Fax: 612-626-2655 |
Dr. Christina L Bender, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 3930 Northwoods Dr, Arden Hills, MN 55112 Phone: 651-490-6775 Fax: 651-490-6754 |
Dr. Christopher S. Hipp, DDS Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Medicare Enrolled Practice Location: 3930 Northwoods Dr, Arden Hills, MN 55112 Phone: 651-490-6732 |
Dr. Margaret R Johnson, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 3930 Northwoods Dr, Arden Hills, MN 55112 Phone: 651-523-8585 Fax: 651-523-8584 |
News Archive
A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient's body than with a conventional cord blood transplant procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting.
On the eve of legislation slated to be introduced this month to reform the Toxic Substances Control Act, almost two dozen organizations representing health care professionals, along with health sector businesses sent letters to Congress urging the passage of strong reform of our nation's chemical regulatory system.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
Each year, an estimated 700,000 persons experience adverse drug events that lead to emergency department visits, according to a study in the October 18 issue of JAMA: The Journal of the American Medical Association.
› Verified 8 days ago